IFRX
InflaRx NV
NASDAQ · Healthcare · Biotechnology · DE
$1.37
−15.74%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +26.9%
- EBIT
- +27.5%
- EPS
- +45.8%
- Free cash flow
- +55.6%
- Operating cash flow
- +55.7%
Forward estimates
Based on analyst estimates
- Revenue
- +115.2%
- EBITDA
- +76.5%
- EPS
- +4.9%
Three-year CAGR
- Revenue
- -31.8%
- EBITDA
- +0.9%
- EBIT
- +8.8%
- Net income
- +0.9%
- EPS
- +15.4%
- Free cash flow
- +30.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026